01P.DU Stock Analysis
01
Attractive
Based on Eyestock quantitative analysis, 01P.DU`s fundamental data and valuation indicate an investment grade of Attractive at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Undervalued
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 5,200 full-time employees. The company went IPO on 2016-08-11. The firm is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The firm's drug development services focuses on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.